Emerging anticoagulants

Expert Opinion on Emerging Drugs

Volumn 16, Issue 1, 2011, Pages 31-44

  Denas, Gentian ^a   Pengo, Vittorio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

anticoagulants; aptamers; factor Xa; inhibitors; LMWHs; novel; thrombin

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; ANTIVITAMIN K; BEMIPARIN; BETRIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 5A INHIBITOR; BLOOD CLOTTING FACTOR 9A INHIBITOR; BLOOD CLOTTING INHIBITOR; BMS 56224701; CERTOPARIN; CLIVARINA; DABIGATRAN ETEXILATE; DALTEPARIN; DU 176 B; EMBOLEX; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; FLOVAGATRAN; FONDAPARINUX; HEPARIN; IDRABIOTAPARINUX; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; M 118; N [2 [4 (1 METHYL 4 PIPERIDINYL) 1 PIPERAZINYL] 2 OXO 1 PHENYLETHYL] 1H INDOLE 6 CARBOXAMIDE; NADROPARIN; OTAMIXABAN; PARNAPARIN; PHENPROCOUMON; PROTAMINE SULFATE; RB 006; RB 007; RECOMBINANT THROMBOMODULIN; REVIPARIN; RIVAROXABAN; SEMULOPARIN; SPP 200; SSR 126517 E; TB 402; THROMBIN INHIBITOR; TINZAPARIN; TTP 889; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; XIMELAGATRAN; YM 150; ZIBOR;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ANTICOAGULATION; BLEEDING; BLOOD CLOTTING DISORDER; CLINICAL TRIAL (TOPIC); DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMBOLISM; HEALTH CARE PERSONNEL; HEMODIALYSIS; HUMAN; IMMUNE MEDIATED INJURY; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; LOW DRUG DOSE; LUNG EMBOLISM; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OSTEOPOROSIS; PATIENT COMPLIANCE; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE THROMBOSIS; REVIEW; RISK FACTOR; SINGLE DRUG DOSE; STROKE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 79952152988     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2011.527947     Document Type: Review

References (97)

1. World Health Organization. Global Strategy on Diet, Physical Activity and Health - Cardiovascular Disease: Prevention and Control 2010. Available from: http://www.who.int/dietphysicalactivity/publications/facts/cvd/en/index.html [Cited 11 September 2010]
2. Chockalingam A, Balaguer-Vintro I, Achutti A, et al. The World Heart Federation's white book: impending global pandemic of cardiovascular diseases: challenges and opportunities for the prevention and control of cardiovascular diseases in developing countries and economies in transition. Can J Cardiol 2000;16(2):227-9
3. Goldhaber SZ. Preventing pulmonary embolism and deep vein thrombosis: a 'call to action' for vascular medicine specialists. J Thromb Haemost 2007;5(8):1607-9 (Pubitemid 47091399) (Pubitemid 47091399)
4. Jerjes-Sanchez C. Venous and arterial thrombosis: a continuous spectrum of the same disease? Eur Heart J 2005;26(1):3-4
5. Sobieszczyk P, Fishbein MC, Goldhaber SZ. Acute pulmonary embolism: don't ignore the platelet. Circulation 2002;106(14):1748-9
6. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th edition. Chest 2008;133(Suppl 6):160S-198S. (Pubitemid 351892967) (Pubitemid 351892967)
7. Krishnaswamy A, Lincoff AM, Cannon CP. The use and limitations of unfractionated heparin. Crit Pathw Cardiol 2010;9(1):35-40
8. Sasisekharan R, Shriver Z. From crisis to opportunity: a perspective on the heparin crisis. Thromb Haemost 2009;102(5):854-8
9. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th edition. Chest 2008;133(Suppl 6):340S-380S (Pubitemid 351892970) (Pubitemid 351892970)
10. Shaughnessy SG, Young E, Deschamps P, Hirsh J. The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood 1995;86(4):1368-73
11. Nenci GG. Low molecular weight heparins: are they interchangeable? No. J Thromb Haemost 2003;1(1):12-13
12. Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th edition. Chest 2008;133(Suppl 6):141S-159S. (Pubitemid 351892966) (Pubitemid 351892966)
13. Adiguzel C, Jeske WP, Hoppensteadt D, et al. Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products. Clin Appl Thromb Hemost 2009;15(2):137-44
14. Jeske WP, Walenga JM, Hoppensteadt DA, et al. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins. Semin Thromb Hemost 2008;34(01):74-85 (Pubitemid 351640883) (Pubitemid 351640883)
15. Stafford DW. The vitamin K cycle. J Thromb Haemost 2005;3(8):1873-8 (Pubitemid 41716574) (Pubitemid 41716574)
16. Visser LE, van Schaik RH, van Vliet M, et al. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Thromb Haemost 2004;92(1):61-6 (Pubitemid 39010868) (Pubitemid 39010868)
17. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335(8):540-6 (Pubitemid 26272308) (Pubitemid 26272308)
18. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996;348(9025):423-8 (Pubitemid 26267872) (Pubitemid 26267872)
19. Denas G, Marzot F, Offelli P, et al. Effectiveness and safety of a management protocol to correct over-anticoagulation with oral vitamin K: a retrospective study of 1,043 cases. J Thromb Thrombolysis 2009;27(3):340-7
20. Denas G, Cucchini U, Iliceto S, Pengo V. An oral vitamin K protocol to reverse over-anticoagulation in patients presenting with an International Normalised Ratio above 10.0. Thromb Haemost 2009;101(2):410-11
21. Crowther MA, Ageno W, Garcia D, et al. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med 2009;150(5):293-300
22. Pengo V, Cucchini U, Denas G, et al. Standardized low-molecular-weight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: an inception cohort management study. Circulation 2009;119(22):2920-7
23. Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th edition. Chest 2008;133(Suppl 6):299S-339S (Pubitemid 351894915) (Pubitemid 351894915)
24. Flaker GC, Gruber M, Connolly SJ, et al. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Am Heart J 2006;152(5):967-73 (Pubitemid 44637136) (Pubitemid 44637136)
25. Bousser MG, Bouthier J, Buller HR, et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 2008;371(9609):315-21
26. Lazo-Langner A, Rodger MA, Wells PS. Lessons from ximelagatran: issues for future studies evaluating new oral direct thrombin inhibitors for venous thromboembolism prophylaxis in orthopedic surgery. Clin Appl Thromb Hemost 2009;15(3):316-26
27. Weitz JI, Hirsh J, Samama MM. New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th edition. Chest 2008;133(Suppl 6):234S-256S (Pubitemid 351892968) (Pubitemid 351892968)
28. Harenberg J, Vukojevic Y, Mikus G, et al. Long elimination half-life of idraparinux may explain major bleeding and recurrent events of patients from the van Gogh trials. J Thromb Haemost 2008;6(5):890-2 (Pubitemid 351524554) (Pubitemid 351524554)
29. Buller HR, Cohen AT, Davidson B, et al. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007;357(11):1094-104 (Pubitemid 47443214) (Pubitemid 47443214)
30. Harenberg J, Jorg I, Vukojevic Y, et al. Anticoagulant effects of idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials. Eur J Clin Pharmacol 2008;64(6):555-63
31. Trellu M, Perez Y, Ortiz J, et al. Bioequipotency of idraparinux and biotinylated idraparinux after single dose in healthy subjects [abstract]. J Thromb Haemost 2007;5(Suppl 2):P-T-678
32. Buller H, Destors JM, Gallus A, et al. Idrabiotaparinux, a biotinylated long-acting anticoagulant, in the treatment of deep venous thrombosis (EQUINOX study): safety, efficacy, and reversibility by avidin. Blood (ASH Annual Meeting Abstracts) 2008;112(18):abstract 32
33. Savi P, Herault JP, Duchaussoy P, et al. Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy. J Thromb Haemost 2008;6(10):1697-706
34. Paty I, Trellu M, Destors JM, et al. Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion. J Thromb Haemost 2010;8(4):722-9
35. Harenberg J. Development of idraparinux and idrabiotaparinux for anticoagulant therapy. Thromb Haemost 2009;102(5):811-15
36. Guertin KR, Choi YM. The discovery of the factor Xa inhibitor otamixaban: from lead identification to clinical development. Curr Med Chem 2007;14(23):2471-81 (Pubitemid 47618035) (Pubitemid 47618035)
37. Sabatine MS, Antman EM, Widimsky P, et al. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. Lancet 2009;374(9692):787-95
38. Viskov C, Just M, Laux V, et al. Description of the chemical and pharmacological characteristics of a new hemisynthetic ultra-low-molecular- weight heparin, AVE5026. J Thromb Haemost 2009;7(7):1143-51
39. Dubruck C, Karimi-Anderesi N, Lunven C, et al. Pharmacokinetics of a new, ultra-low molecular weight heparin, semuloparin (AVE5026), in healthy subjects. Results from the first phase I studies [poster 1073]. 51st ASH Annual Meeting; 2009. Available from: http://ash.confex.com/ash/2009/webprogram/Paper22065.html [Cited 23 June 2010]
40. Lassen MR, Dahl OE, Mismetti P, et al. AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery - TREK: a dose-ranging study. J Thromb Haemost 2009;7(4):566-72
41. Turpie AG, Agnelli G, Fisher W, et al. Benefit-to-risk profile of the ultra-low-molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE): a meta-analysis of 3 major orthopaedic surgery studies [abstract]. Pathophysiol Haemost Thromb 2009/2010;37(Suppl 1):OC332
42. Fisher W, Agnelli G, George D, et al. The ultra-low-molecular-weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) after hip fracture surgery [abstract]. Pathophysiol Haemost Thromb 2009/2010;37(Suppl 1):P330
43. Fisher W, Agnelli G, George D, et al. Extended venous thromboembolism (VTE) prophylaxis after hip fracture surgery with the ultra-low-molecularweight heparin (ULMWH) semuloparin [abstract]. Pathophysiol Haemost Thromb 2009/2010;37(Suppl 1):OC681
44. Mouret P, Agnelli G, Fisher W, et al. The ultra-low-molecular-weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) after elective hip replacement surgery [abstract]. Pathophysiol Haemost Thromb 2009/2010;37(Suppl 1):OC316
45. Lassen MR, Agnelli G, Fisher W, et al. The ultra-low-molecular-weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) after elective knee replacement surgery [abstract]. Pathophysiol Haemost Thromb 2009/2010;37(Suppl 1):OC331
46. Hoppensteadt DA, Jeske W, Walenga JM, Fareed J. AVE5026: a new hemisynthetic ultra low molecular weight heparin (ULMWH) with enriched anti-Xa activity and enhanced antithrombotic activity for management of cancer associated thrombosis [abstract]. J Clin Oncol 2008;26(Suppl):14653
47. Eikelboom JW, Zelenkofske SL, Rusconi CP. Coagulation factor IXa as a target for treatment and prophylaxis of venous thromboembolism. Arterioscler Thromb Vasc Biol 2010;30(3):382-7
48. Eikelboom JW, Weitz JI. Otamixaban in acute coronary syndromes. Lancet 2009;374(9692):762-4
49. Chan MY, Rusconi CP, Alexander JH, et al. A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor. J Thromb Haemost 2008;6(5):789-96 (Pubitemid 351524539) (Pubitemid 351524539)
50. Chan MY, Cohen MG, Dyke CK, et al. Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation 2008;117(22):2865-74 (Pubitemid 351787073) (Pubitemid 351787073)
51. Cohen MG, Drew AP, Rossi JS, et al. Factor IXa inhibition with REG1 provides rapid onset, stable and actively controlled anticoagulation during PCI [abstract]. J Am Coll Cardiol 2010;55(10A):, A206.E1940
52. Cohen MG, Purdy DA, Rossi JS, et al. First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention. Circulation 2010;122(6):614-22
53. Linhardt RJ. Chemical and enzymatic methods for the depolymerization and modification of heparin. Carbohydrates-synthetic methods and applications in medicinal chemistry. Kodansha/VCH Publishers, Tokyo/Weinheim; 1992. p. 385-401
54. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358(21):2218-30 (Pubitemid 351724451) (Pubitemid 351724451)
55. Rao SV, Melloni C, Myles-Dimauro S, et al. Evaluation of a new heparin agent in percutaneous coronary intervention: results of the phase 2 evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial. Circulation 2010;121(15):1713-21
56. Melloni C, Fier I, Roach J, et al. Design and rationale of the Evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) trial. Am Heart J 2009;158(5):726-33
57. Verhamme P, Pakola S, Jensen TJ, et al. Tolerability and pharmacokinetics of TB-402 in healthy male volunteers. Clin Ther 2010;32(6):1205-20
58. Verhamme P, Verhaeghe R, Ageno W, et al. Single intravenous administration of TB-402 for the prophylaxis of VTE after total knee replacement surgery [abstract]. Pathophysiol Haemost Thromb 2009/2010;37(Suppl 1):P509
59. Mohri M, Sugimoto E, Sata M, Asano T. The inhibitory effect of recombinant human soluble thrombomodulin on initiation and extension of coagulation - a comparison with other anticoagulants. Thromb Haemost 1999;82(6):1687-93
60. Sadler JE. Thrombomodulin structure and function. Thromb Haemost 1997;78(1):392-5 (Pubitemid 27289273) (Pubitemid 27289273)
61. Mohri M, Suzuki M, Sugimoto E, et al. Effects of recombinant human soluble thrombomodulin (rhs-TM) on clot-induced coagulation in human plasma. Thromb Haemost 1998;80(6):925-9 (Pubitemid 28556694) (Pubitemid 28556694)
62. Mohri M. ART-123: recombinant human soluble thrombomodulin. Cardiovasc Drug Rev 2000;18(4):312-25 (Pubitemid 32046396) (Pubitemid 32046396)
63. Maruyama I. Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation. Thromb Haemost 1999;82(2):718-21
64. Kearon C, Comp P, Douketis J, et al. Dose-response study of recombinant human soluble thrombomodulin (ART-123) in the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2005;3(5):962-8 (Pubitemid 41632827) (Pubitemid 41632827)
65. Wienen W, Stassen JM, Priepke H, et al. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 2007;98(1):155-62 (Pubitemid 47078782) (Pubitemid 47078782)
66. Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008;36(2):386-99 (Pubitemid 351185753) (Pubitemid 351185753)
67. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet 2009;48(1):1-22
68. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5(11):2178-85 (Pubitemid 47617868) (Pubitemid 47617868)
69. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007;370(9591):949-56 (Pubitemid 47393577) (Pubitemid 47393577)
70. Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009;24(1):1-9
71. Huo M. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: the RE-NOVATE II randomized trial. Presented at 15th Congress of the European Hematology Association; 10 - 13 June 2010; Barcelona, Spain
72. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361(24):2342-52
73. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361(12):1139-51
74. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-429
75. Mueck W, Borris LC, Dahl OE, et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008;100(3):453-61
76. Eriksson BI, Borris L, Dahl OE, et al. Oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006;4(1):121-8
77. Eriksson BI, Borris LC, Dahl OE, et al. A once-daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 2006;114(22):2374-81 (Pubitemid 44847454) (Pubitemid 44847454)
78. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358(26):2765-75 (Pubitemid 351930851) (Pubitemid 351930851)
79. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358(26):2776-86 (Pubitemid 351930852) (Pubitemid 351930852)
80. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008;372(9632):31-9
81. Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009;373(9676):1673-80
82. The Executive Steering Committee, on behalf of the ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010;159(3):340-47 e1
83. Lassen MR, Davidson BL, Gallus A, et al. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007;5(12):2368-75 (Pubitemid 350154345) (Pubitemid 350154345)
84. Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009;361(6):594-604
85. Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010;375(9717):807-15
86. Lassen MR, Gallus A, Raskob GE, et al. Randomized double-blind comparison of apixaban and enoxaparin for thromboprophylaxis after hip replacement: the ADVANCE-3 trial [abstract]. Pathophysiol Haemost Thromb 2009/2010;37(Suppl 1):OC356
87. Connolly S. A Phase III Study of Apixaban in Patients With Atrial Fibrillation (AVERROES). Presented at European Society of Cardiology 2010 Congress; 31 August 2010; Stockholm, Sweden
88. Fuji T, Fujita S, Tachibana S, Kawai Y. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. J Thromb Haemost 2010. [Epub ahead of print]
89. Weitz JI, Connolly SJ, Patel I, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 2010;104(3):633-41
90. Turpie AG, Bauer KA, Davidson BL, et al. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost 2009;101(1):68-76
91. Garcia D, Milner PG, Canafax DM, Ellis DJ. Results of the EmbraceAC Trial: A Head-to-Head Comparison of Warfarin with Tecarfarin, A New Anticoagulant. 51st ASH Annual Meeting and Exposition. American Society of Hematology, New Orleans, LA; 2009
92. Buller HR, Lensing AW, Prins MH, et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 2008;112(6):2242-7
93. Mega JL, Braunwald E, Mohanavelu S, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009;374(9683):29-38
94. Alexander JH, Becker RC, Bhatt DL, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009;119(22):2877-85
95. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation 2009;119(23):3028-35
96. Newby LK, LaPointe NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 2006;113(2):203-12
97. World Health Organization. The World Health Report 2008. Primary Health Care - Now More Than Ever; 2008. Available from: http://www.who.int/whr/2008/ whr08-en.pdf [Cited 11 September 2010]